FDA Label Decisions On Paxil Don't Deter Verdict Against GSK In Suicide Case
Executive Summary
Chicago jury finds GSK failed to adequately warn about risk of suicidal behavior in patients over age 24 taking paroxetine; GSK argued that FDA had found no increased risk in this population.
You may also be interested in...
FDA Communications Key To Court Dismissal Of Diabetes Product Liability Suits
Merck, AstraZeneca and Novo Nordisk's incretin mimetics win as district judge cites FDA’s history of rejecting pancreatic cancer warnings.
FDA Proposes Unilateral Generic Drug Label Changes, Signaling End To Liability Shield
FDA proposed rule would allow ANDA holders to unilaterally make label changes prior to FDA’s approval; NDA and other ANDA holders would have 30 days to revise their labels once FDA approves the change.
GSK’s DoJ Settlement Requires Execs To Forfeit Bonuses If Misconduct Occurs
GlaxoSmithKline pleads guilty to promoting Paxil and Wellbutrin off-label and failing to report Avandia safety data to FDA; civil portion of settlement resolves off-label and kickback allegations involving nine products. New corporate integrity agreement gives OIG authority to require a recall.